Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Price Target at $27.80

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $27.80.

A number of research firms recently weighed in on TBPH. Oppenheimer initiated coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target for the company. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. BTIG Research raised their target price on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, November 26th. B. Riley initiated coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a “buy” rating and a $28.00 price target on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president directly owned 277,695 shares in the company, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares during the period. Park West Asset Management LLC grew its holdings in Theravance Biopharma by 0.6% during the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock worth $16,112,000 after acquiring an additional 11,256 shares during the period. Geode Capital Management LLC grew its holdings in Theravance Biopharma by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after acquiring an additional 3,416 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Theravance Biopharma by 6.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock valued at $11,193,000 after acquiring an additional 44,634 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at $10,611,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Stock Down 1.3%

Shares of TBPH stock opened at $18.57 on Friday. The company has a market capitalization of $940.94 million, a P/E ratio of 32.58 and a beta of 0.14. Theravance Biopharma has a 12-month low of $7.90 and a 12-month high of $20.33. The firm has a 50-day moving average price of $16.90 and a 200 day moving average price of $14.04.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The firm had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. As a group, research analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.